FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to oncology and may be used in treating papillary renal cell carcinoma (pRCC) in a mammal. That is ensured by administering an effective amount of CCI-779 into a mammal in need thereof. There are also presented using CCI-779 to produce therapeutic agents and a method of treating papillary renal cell carcinoma in the mammal with no alpha interferon production.
EFFECT: group of inventions provides treating pRCC referred to as non-clear cell carcinomas; what is also ensured is a delay in disease progression and a prolonged patient's lifespan.
17 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
| ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
| ANTICANCER COMBINATIONS OF CCI-779 AND RITUXIMAB | 2005 |
|
RU2389508C2 |
| COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
| COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR | 2009 |
|
RU2538683C2 |
| COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR | 2011 |
|
RU2585489C2 |
| USE OF COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT | 2006 |
|
RU2461630C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| ANTI-TUMOR COMPOSITIONS CONTAINING RAPAMICINE DERIVATIVE AND AROMATASE INHIBITOR | 2004 |
|
RU2355399C2 |
| CCI-779 FOR AMPHICYTE LYMPHOMA TREATMENT | 2004 |
|
RU2358731C2 |
